subscribeSubscribe
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease

FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
PHARMACEUTICAL-TECHNOLOGY
20 Apr 2024
Share Share
Takeda Pharms USA`s Entyvio (vedolizumab) Receives Suppl Approval In the US

Takeda Pharms USA`s Entyvio (vedolizumab) Receives Suppl Approval In the US

FDA
19 Apr 2024
Share Share
Takeda Pharms USA`s Biologic Entyvio (vedolizumab) Receives Suppl Approval In the US

Takeda Pharms USA`s Biologic Entyvio (vedolizumab) Receives Suppl Approval In the US

FDA
18 Apr 2024
Share Share
Takeda Pharma`s Biologic Entyvio (vedolizumab) Receives Approval in the U.S.

Takeda Pharma`s Biologic Entyvio (vedolizumab) Receives Approval in the U.S.
FDA
23 Feb 2024
Share Share
Polpharma Biologics` biosimilar shows PK/PD comparability to blockbuster Entyvio

Polpharma Biologics` biosimilar shows PK/PD comparability to blockbuster Entyvio
PR NEWSWIRE
21 Feb 2024
Share Share
U.S. FDA Approves Subcutaneous Administration of Takeda`s ENTYVIO

U.S. FDA Approves Subcutaneous Administration of Takeda`s ENTYVIO
BUSINESSWIRE
27 Sep 2023
Share Share
Takeda Pharmaceutical`s Biologic Entyvio (Vedolizumab) Receives Approval in the U.S.

Takeda Pharmaceutical`s Biologic Entyvio (Vedolizumab) Receives Approval in the U.S.
FDA
27 Sep 2023
Share Share
Morphic`s stock sinks as data on oral Entyvio rival disappoint

Morphic`s stock sinks as data on oral Entyvio rival disappoint
Nick Paul Taylor FIERCE BIOTECH
25 Sep 2023
Share Share
Takeda Announces FDA Acceptance of BLA for Administration of ENTYVIO

Takeda Announces FDA Acceptance of BLA for Administration of ENTYVIO
BUSINESSWIRE
13 Sep 2023
Share Share
Takeda Announces FDA Acceptance of BLA Resubmission for Invgl Sub adm of Entyvio

Takeda Announces FDA Acceptance of BLA Resubmission for Invgl Sub adm of Entyvio
BUSINESSWIRE
27 Apr 2023
Share Share